VETOQUINOL Corporate brochure 2007 (year 2007)

Vétoquinol is focussing on the treatments of three types of diseases. INFECTIOUS DISEASES Vétoquinol develops different families of antibiotics, with protocols adapted for different species. This approach combines effective treatments and respect for the environment and the consumer. In the European market, Vétoquinol is no. 1 in the segment of topical ear products for companion animals, no. 2 in oral anti-infectives for companion animals and no. 3 in injectable anti-infectives. Launched in 1995 and source of successive innovations, Marbocyl ® - the Group’s flagship product – is one of the five most popular brands of anti-infectives in Europe. This antibiotic with numerous indications treats both livestock and companion animals. Aurizon ® and Oridermyl ® , prescribed for treating otitis in dogs and cats, are also among the market leaders in Europe. Launched more recently, other brands such as Clavaseptin ® and Enisyl ® make a considerable contribution to the Group’s growth in the anti- infective sector. PAIN AND INFLAMMATION Alleviating an animal’s pain is an ethical challenge which is very much in demand as the animal’s well- being is more and more important. It is also a medical challenge as pain has detrimental effects on health. Products in this area are therefore aimed at preventing pain, particularly during surgery, reducing it when it appears and eventually managing chronic situations by improving the animal’s comfort, for example in cases of osteoarthritis. Vétoquinol satisfies these various needs thanks to a complete range of products: • for surgery, an anaesthetic specifically developed for companion animals, Alfaxan ® , and the distribution of a range of surgical equipment, • a nonsteroidal anti-inflammatory (NSAID) for the management of acute pain and inflammation, Tolfedine ® for dogs and cats and Tolfine ® for livestock, • two NSAIDs for managing chronic pain, Rimifin ® in Europe and Vetprofen ® in the United States, • two ranges of chondro-protective nutraceutical supplements for managing osteoarthritis, Flexadin ® and Caniviton ® . CARDIOLOGY AND NEPHROLOGY Cardiac and renal insufficiency are the most common chronic diseases affecting respectively elderly dogs and cats. Vétoquinol has developed some innovative treatments in this fast-growing sector. Prilium ® , a product for dogs with cardiac insufficiency, has an innovative galenic formulation: the only one in its category to be marketed in a liquid form. It is available in most European countries, Australia and New Zealand. The rest of the range is dedicated to treating renal insufficiency.With the success of other innovative brands - Ipakitine ® in Europe and North America and Azodyl ® in the United States and Canada – the Group is consolidating its position as experts in this area, by offering training tools such as Vétoquinol Academia, and regular innovations (existing and future products). Activity report 2007 / Products #25 Dr. Natarajan Ranganathan Vice-President R&D of Kibow Biotech Inc. “In 2006, U.S. and Canadian marketing and distribution rights of Kibow Biotics ® were sold to Vétoquinol. In 2007, we have extended our partnership worldwide. Vétoquinol is a recognized leader in the field of animal health as demonstrated by its portfolio of outstanding innovative products, and by its steady growth”. Tony Cooley Jurox Head of sales and marketing “14 months after Vetoquinol’s extremely successful launch of Alfaxan ® in the United Kingdom, continental Europe was the next logical step in the collaboration on Alfaxan ® for both organizations.” “